On May 11, 2022, Medipure Pharmaceuticals Inc. ("MPI") and Medipure Holdings Inc. ("MHI", together with MPI, “Medipure" or the “Companies") both filed a Notice of Intention to Make a Proposal ("NOI") pursuant to Section 50.4(1) of the Bankruptcy and Insolvency Act (the "BIA", the “BIA Proceedings"). Deloitte Restructuring Inc. (“Deloitte") was appointed as the proposal Trustee of the Companies (the “Proposal Trustee"). Pursuant to Section 69 of the BIA, all proceedings against MPI and MHI are stayed as of that date.
On August 19, 2022 (the “Initial Order Date"), on application by the Companies, the Supreme Court of British Columbia (the “Court") made an order (the “Initial Order") granting the Companies protection from their creditors pursuant to the Companies Creditors Arrangement Act, R.S.C. 1985 as amended (the “CCAA"). Under the Initial Order, Deloitte Restructuring Inc. (“Deloitte") was appointed as the Monitor of the Companies with enhanced powers (the “Monitor"). These proceedings (the “CCAA Proceedings") are a continuation of the BIA Proceedings under which Deloitte was appointed as the Proposal Trustee. The Initial Order discharges Deloitte as the Proposal Trustee of the Companies under the BIA Proceedings.
On November 1, 2022, the assets of the Companies were sold to Apogee Pharmaceuticals Inc. and the Monitor was discharged subject to completion of its incidental duties to complete the CCAA Proceedings.
On February 2, 2023, the Monitor, pursuant to the provisions of the BIA and an order from the CCAA Proceedings, caused MPI and MHI to file assignments into bankruptcy for the general benefit of creditors. Deloitte was appointed as licensed insolvency trustee of the estates of the bankrupts (the “Trustee").
Publicly available documents related to these proceedings will be posted to this website.
If you have any questions on this matter, please contact Jordan Yin of the
Trustee's office at 604-640-5089 or email@example.com
BIA - NOI Proceedings
BIA - Bankruptcy Proceedings
Mar 7, 2023